PreveCeutical Medical Inc.
PreveCeutical Medical Inc.
- ISIN: CA74141E1043
- Land: .
Nachricht vom 17.06.2019 | 14:03
PreveCeutical Announces Further Positive Results from its Dual Gene Therapy Research Program
DGAP-News: PreveCeutical Medical Inc. / Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2019) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to provide positive results from research conducted for its dual gene therapy research program (the "Program").
PreveCeutical previously identified four or more novel siRNA constructs, each of which preferentially targeted the gene of interest while reducing the gene's expression by no less than 80% compared to a random siRNA (control) sequence (see news release dated January 14, 2019).
The siRNA constructs represent the "therapeutic" component of the proposed gene therapy and are an important part of the gene therapy approach for potential application in type 2 diabetes and obesity. PreveCeutical's research team has now identified and finalised a panel of highly potent and novel siRNA-candidates, each of which significantly (≥50%) silence the target gene and protein in mice and human-derived cells of interest. The lead siRNA sequences comprise those directed to the human variant of PTP-1B, and distinct sequences directed towards the mouse variant of PTP-1B. Synthetic efforts will now focus on introducing proprietary chemistries that enhance the biostability and thermostability of the novel siRNA sequences to generate modified siRNA sequences ("Smart-siRNAs"). Once the first series of Smart-siRNA's are successfully developed, they are expected to be re-screened in cell-based assays to re-affirm their potency. This is anticipated to pave the way for evaluation in planned rodent models of disease, which would constitute the final phase of the Program.
PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar stated, "We are pleased with the progress being made given that these novel, potent siRNA constructs constitute the most crucial part of the gene therapy approach. This is a positive step in the right direction for the pursuit of our goal to achieve a successful dual gene therapy program."
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; a soluble gel drug delivery program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
On Behalf of the Board of Directors
"Dr. Makarand (Mak) Jawadekar"
For further information, please contact:
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, matters related to the Company's current and planned research and development programs, including the Program, the efficacy of the series of lead siRNA constructs and the potency of the Smart-siRNAs, the Company's anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, performance, industry trends and growth opportunities. Actual results could also differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, execute its proposed business plans, complete its research and product development programs as planned, including the Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/45644
Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/45644
|Company:||PreveCeutical Medical Inc.|
|EQS News ID:||825781|
|End of News||DGAP News Service|
Event im Fokus
14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie
11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix
Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.
Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet
Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.
Der AKTIONÄR News
20. Oktober 13:00 Opening Bell: Dow Jones vor Auftaktplus; Microsoft, Procter&Gamble, ...
20. Oktober 12:49 US-Vorbörse: Neue Konjunktur-Paket- und Impfstoffhoffnungen – ...
20. Oktober 12:33 Volkswagen: Anleger aufgepasst, wichtiges Datum!
20. Oktober 12:21 „Tesla bekommt Konkurrenz“ – Wasserstoff-Lösung mit 200 Prozent mehr ...
News im Fokus
Munich Re erzielt Quartalsergebnis von ca. 200 Mio. €
20. Oktober 2020, 15:37
Original-Research: CytoTools AG (von BankM AG): Kaufen
19. Oktober 2020